BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1173 related articles for article (PubMed ID: 15909461)

  • 21. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
    Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
    J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
    Ekşi F; Ozer G; Balci I
    Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
    Hwang KP; Tang YF; Shen YH
    J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Short communication: Extended-spectrum beta-lactamase production in Klebsiella pneumoniae strains isolated from blood cultures and their antibiotic susceptibilities].
    Işik F; Arslan U; Tuncer I
    Mikrobiyol Bul; 2008 Jan; 42(1):131-6. PubMed ID: 18444571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test result for isolates of Escherichia coli and Klebsiella pneumoniae: results from the SENTRY Asia-Pacific Surveillance Program.
    Bell JM; Chitsaz M; Turnidge JD; Barton M; Walters LJ; Jones RN
    J Clin Microbiol; 2007 May; 45(5):1478-82. PubMed ID: 17344367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
    Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and antimicrobial susceptibility of extended-spectrum beta lactamases-producing
    Mofolorunsho KC; Ocheni HO; Aminu RF; Omatola CA; Olowonibi OO
    Afr Health Sci; 2021 Jun; 21(2):505-512. PubMed ID: 34795702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic-resistance patterns and frequency of extended-spectrum beta-lactamase-producing isolates of Klebsiella pneumoniae in Tehran.
    Feizabadi MM; Etemadi G; Yadegarinia D; Rahmati M; Shabanpoor S; Bokaei S
    Med Sci Monit; 2006 Nov; 12(11):BR362-5. PubMed ID: 17072265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin].
    Hernández MS; García JA; Muñoz JL
    Rev Esp Quimioter; 2009 Mar; 22(1):25-9. PubMed ID: 19308743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriuria by extended-spectrum Beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran.
    Aminzadeh Z; Sadat Kashi M; Sha'bani M
    Iran J Kidney Dis; 2008 Oct; 2(4):197-200. PubMed ID: 19377237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
    Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
    Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissemination of SHV-12 and CTX-M-type extended-spectrum beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea.
    Ryoo NH; Kim EC; Hong SG; Park YJ; Lee K; Bae IK; Song EH; Jeong SH
    J Antimicrob Chemother; 2005 Oct; 56(4):698-702. PubMed ID: 16141280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.